Artiva Biotherapeutics nets $120m Series B

Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company, has secured $120 million in Series B financing.

1 March 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles